(PharmaNewsWire.Com, January 17, 2020 ) This report provides a detailed overview of the major drivers, restraints, challenges, opportunities, and strategies impacting the protein assays market, along with revenue estimates & forecasts and market share analysis.
The growth of the protein assays market can be attributed to the increasing pharmaceutical & biotech R&D expenditure and favorable government funding scenario for proteomics research. Based on the analysis of strategic developments undertaken by market players between 2014 and 2017, the key strategy followed by most companies in the market is expansions and agreements, partnerships, and collaborations.
Some of the leading players that adopted this strategy include Thermo Fisher Scientific (U.S.), Merck KGaA (Germany), Cell Signaling Technology, Inc. (U.S.), Abcam plc. (U.S.), and PerkinElmer Inc. (U.S.).
Thermo Fisher Scientific was leading player in the protein assay products market in 2016. The company focuses on organic and inorganic strategies in order to strengthen its position in the market. In 2015, the company acquired Alfa Aesar (U.S.), and in 2014 acquired Life Technology Corporation (U.S.) these acquisitions helped the company strengthen its protein assays product portfolio.
In 2017, the company acquired Core Informatics (U.S.) and in 2016 acquired Affymetrix (U.S.) in order to enhance its share in the market. In 2016, the company expanded its clinical trials support in Japan. In 2015, the company opened its new clinical services facility in Singapore. These expansions helped the company to amplify its geographic reach.
Merck KGaA was another leading player in the protein assay products market in 2016. It focuses mainly on collaborations, acquisitions, and expansions to strengthen its position in the market. In November 2015, the company acquired Sigma Aldrich (U.S.). This acquisition helped it to increase its product portfolio and its geographic presence.
The company also focuses on expansions to strengthen its market share. In September 2016, the company expanded its R&D facility in China. This helped the company to increase its protein assays product portfolio. In March 2015, the company collaborated with Illumina (U.S.). This collaboration helped the company to develop assays used in clinical trials.
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
